The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma
Official Title: An Open, Dose Escalation/Dose Exploration, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single/Multiple Infusion of CT0180 Injection in Patients With Advanced Hepatocellular Carcinoma
Study ID: NCT04756648
Brief Summary: A Phase I Clinical Study ofCT0180 cells in Patients with Advanced Hepatocellular Carcinoma
Detailed Description: Primary objectives: Evaluate the safety and tolerance of CT0180 cells in patients with advanced hepatocellular carcinoma within 28 days after the first infusion Secondary objectives: * Evaluate the metabolic kinetics of CT0180 cells ; · Evaluate overall safety and tolerability ; · Evaluate the initial efficacy of CT0180 cell infusion in the treatment of advanced hepatocellular carcinoma with positive Glypican-3(GPC3 )expression.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
First affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China
Name: Tingbo Liang
Affiliation: The First Affiliated Hospital, Zhejiang University
Role: PRINCIPAL_INVESTIGATOR